GENENTECH’s $75 MIL. R&D FACILITY SCHEDULED TO OPEN IN MID-1992
GENENTECH's $75 MIL. R&D FACILITY SCHEDULED TO OPEN IN MID-1992, the company announced Oct. 12. The three-building center "will rank among the largest commercial or academic biotechnology research centers" in the world, Genentech said. Groundbreaking took place the day of the announcement. The new facility is the first fruit of Genentech's merger deal with Roche Holding Ltd., which completed the acquisition of a 60% equity stake in the biotech company on Sept. 7. Genentech has more than $600 mil. in cash in the wake of Roche's investment. Located on Genentech's 72-acre South San Francisco campus, the buildings will total 225,000 square feet and accomodate 420 research staffers when completed. Genentech said that "one of the principal goals of the [new facility's] design is to establish an informal style, which facilitates collaboration between research departments and maintains the Genentech corporate culture." The new facility will allow Genentech to gradually expand its R&D staff, which now numbers approximately 700. In addition, the three-building center will help alleviate overcrowding in the company's current R&D facility and allow upgrades of the company's R&D plant. Genentech plans to leave two floors of the center vacant for future expansion. The company noted that "additional expansion...is possible on the 24 acres Genentech owns at the site, of which only eight acres will be used for this project." The company said it has not decided if it will continue to use the current R&D facility, which is leased, after the new one opens. SRG Partnership, a Portland, Oregon-based firm, is the architect of the new facility. San Francisco-based VDK Architects will assume laboratory planning, and Rudolph and Sletten of Foster City, Calif. are contracted to do the construction. The Genentech facility will have structural support that is twice the minimum earthquake standard. Genentech's current research facility was unscathed by the earthquake that hit San Francisco a year ago.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth